Acromegaly Market Report 2026

The acromegaly market size has grown rapidly in recent years. It will grow from $2.56 billion in 2025 to $3.01 billion in 2026 at a compound annual growth rate (CAGR) of 17.5%. The growth in the historic period can be attributed to limited availability of acromegaly diagnostic tools, rising prevalence of growth hormone disorders, increasing hospital and specialty clinic infrastructure, adoption of conventional treatment methods, growing awareness of rare endocrine disorders.

The acromegaly market size is expected to see rapid growth in the next few years. It will grow to $5.84 billion in 2030 at a compound annual growth rate (CAGR) of 18.1%. The growth in the forecast period can be attributed to development of advanced somatostatin analogues, expansion of parenteral treatment options, rising adoption of precision medicine approaches, increasing homecare and outpatient treatment models, integration of digital health and remote monitoring solutions. Major trends in the forecast period include increasing adoption of growth hormone measurement and igf-i testing, rising use of somatostatin analogues and dopamine agonists, expansion of minimally invasive surgery and radiation therapy, growing focus on personalized treatment plans for patients, enhanced awareness and early diagnosis programs.

The growing prevalence of hormonal diseases such as diabetes is expected to drive the growth of the acromegaly market in the coming years. Hormonal diseases, also known as endocrine disorders, are medical conditions caused by dysfunction in the endocrine system, with diabetes being one of the most common and significant. Acromegaly and other endocrine disorders can result from the overproduction of hormones such as growth hormone or cortisol. Additionally, due to the effect of elevated growth hormone levels on insulin production, approximately 50% of individuals with acromegaly may develop insulin resistance or type 2 diabetes mellitus. For instance, in March 2024, data from the Office for Health Improvement and Disparities, a UK-based government department, showed that between March 2022 and March 2023, the percentage of individuals with type 1 diabetes receiving all eight recommended care processes increased by 22%, while for type 2 diabetes, it rose by 21%. During the same period, the percentage achieving target HbA1c levels reached 37.9%, the highest value ever reported by the National Diabetes Audit (NDA). Therefore, the rising prevalence of hormonal diseases is contributing to the growth of the acromegaly market.

Major companies operating in the acromegaly market are focused on developing innovative products and solutions, such as generic lanreotide, to expand treatment options and improve patient outcomes. Generic lanreotide is a non-branded version of a medication used to treat acromegaly and certain neuroendocrine tumors. It functions as a somatostatin analogue, reducing growth hormone secretion and improving patient access to effective treatments. For instance, in October 2024, Teva Pharmaceutical Industries Ltd., an Israel-based pharmaceutical company specializing in generic drugs, launched the first and only generic version of Sandostatin LAR Depot in the United States. The injectable suspension, octreotide acetate, is indicated for the treatment of acromegaly and severe diarrhea associated with carcinoid syndrome, enhancing access to essential therapy for patients in need.

In July 2024, AstraZeneca plc, a UK-based multinational pharmaceutical and biotechnology company, acquired Amolyt Pharma for $1.05 billion. This acquisition strengthens AstraZeneca’s rare disease treatment pipeline, particularly in endocrine and metabolic disorders, as Amolyt’s innovative therapies align with the company’s commitment to advancing patient care and addressing unmet medical needs. Amolyt Pharma is a France-based clinical-stage biopharmaceutical company developing treatments for rare endocrine disorders, including eneboparatide for hypoparathyroidism and AZP-3813, a peptide antagonist for acromegaly.

Major companies operating in the acromegaly market are Pfizer Inc., Johnson & Johnson Private Limited, Merck & Co Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., AstraZeneca plc, GlaxoSmithKline plc, Eli Lilly and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH., Amgen Inc., Allergan Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Ipsen Pharma S.A., Hikma Pharmaceuticals PLC, Lupin Ltd., Recordati S.p.A., Ionis Pharmaceuticals Inc., Amryt Pharma plc, Strongbridge Biopharma plc, Aquestive Therapeutics Inc., Peptron Inc., Crinetics Pharmaceuticals, Chiasma Inc.

North America was the largest region in the acromegaly market in 2025. The regions covered in the acromegaly market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the acromegaly market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the acromegaly market by increasing costs for imported diagnostic devices, medications, and surgical equipment. Segments such as growth hormone measurement kits, somatostatin analogues, and imaging systems are most affected, particularly in regions like north america, europe, and asia-pacific. This has led to higher treatment costs and supply chain adjustments. On the positive side, tariffs have encouraged local manufacturing, promoted regional production of diagnostics and therapeutics, and spurred innovation in treatment technologies.

The acromegaly market research report is one of a series of new reports that provides acromegaly market statistics, including acromegaly industry global market size, regional shares, competitors with a acromegaly market share, detailed acromegaly market segments, market trends and opportunities, and any further data you may need to thrive in the acromegaly industry. This acromegaly market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Acromegaly is a rare hormonal disorder that occurs when the pituitary gland, a small gland at the base of the brain, produces excessive amounts of growth hormone. This overproduction causes enlargement and thickening of bones and tissues in various parts of the body, particularly the hands, feet, and face.

The main types of acromegaly are ectopic acromegaly and acromegaly due to growth hormone excess. Ectopic acromegaly is a rare condition in which excessive growth hormone (GH) is produced from a source outside the pituitary gland. Diagnosis involves methods such as GH and IGF-I measurement, growth hormone suppression tests, imaging, and others. These tests can be administered through various routes, including oral and parenteral. Treatment options include medications, somatostatin analogues, dopamine agonists, growth hormone antagonists, surgery, radiation, and others, and are used by end users such as hospitals, specialty clinics, homecare providers, and others.

The acromegaly market consists of revenues earned by entities by providing hormone replacement therapy, pituitary radiotherapy and lifestyle modifications. The market value includes the value of related goods sold by the service provider or included within the service offering. The acromegaly market also includes sales of octreotide, lanreotide and somavert. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.